Purple biotech reports positive results of cm24 dose escalation in advanced pancreatic cancer patients

Rehovot, israel, july 11, 2023 (globe newswire) -- purple biotech ltd. ("purple biotech" or "the company") (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the completion and data maturity of its phase 1 dose escalation study of cm24, a first-in-class anti-ceacam1 monoclonal antibody addressing multiple tumor types.
PPBT Ratings Summary
PPBT Quant Ranking